TORCH infections

Clinics in Perinatology

Volumn 42, Issue 1, 2015, Pages 77-103

  Neu, Natalie ^a   Duchon, Jennifer ^b   Zachariah, Philip ^b  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Hepatitis B; Hepatitis C; HIV; Parvovirus; Rubella; TORCH; Toxoplasmosis; Treponema pallidum

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BENZATHINE PENICILLIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; MEASLES MUMPS RUBELLA VACCINE; NEVIRAPINE; PYRIMETHAMINE; SULFADIAZINE; ZIDOVUDINE; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT;

BACTERIAL TRANSMISSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFECT; ERYTHEMA INFECTIOSUM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PARVOVIRUS B19; INFECTION PREVENTION; NONHUMAN; PARASITE TRANSMISSION; PERINATAL DEATH; REVIEW; RUBELLA; RUBELLA VIRUS; STILLBIRTH; SYPHILIS; TOXOPLASMOSIS; TREATMENT PLANNING; TREPONEMA PALLIDUM; TREPONEMATOSIS; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS TRANSMISSION; FEMALE; HIV INFECTIONS; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; RUBELLA SYNDROME, CONGENITAL; SYPHILIS, CONGENITAL; TOXOPLASMOSIS, CONGENITAL;

ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; ANTIVIRAL AGENTS; ERYTHEMA INFECTIOSUM; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; RUBELLA SYNDROME, CONGENITAL; SYPHILIS, CONGENITAL; TOXOPLASMOSIS, CONGENITAL;

EID: 84922430395     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2014.11.001     Document Type: Review

References (113)

1. Ott J., Stevens G., Wiersma S. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012, 12:131.
2. Hepatitis B. Available at:. Accessed October 30, 2014. http://www.who.int/mediacentre/factsheets/fs204/en/.
3. Global HIV/AIDS response. Available at:. Accessed October 30, 2014. http://www.who.int/reproductivehealth/topics/rtis/GlobalData_cs_pregnancy2011.pdf?ua.
4. 2012 sexually transmitted diseases surveillance. Available at:. Accessed October 30, 2014. http://www.cdc.gov/std/stats12/syphilis.htm.
5. McAuley J. Congenital toxoplasmosis. JPediatricic Infect Dis Soc 2014, 3(Suppl 1):S30-S35.
6. Tudor Rares O., Remington J., McLeod R., et al. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J 2011, 30(12):1056-1061.
7. Gottlieb S., Pope V., Sternberg M., et al. Prevalence of syphilis seroreactivity in the United States: data from the National Health and Nutrition Examination Surveys (NHANES) 2001-2004. Sex Transm Dis 2008, 35(5):507-511.
8. Pappas G., Roussos N., Falagas M. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009, 39(12):1385-1394.
9. Vaccines and immunizations. Available at:. Accessed October 30, 2014. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt15-crs.html.
10. Cytomegalovirus (CMV) and congenital CMV infection. Available at:. Accessed October 30, 2014. http://www.cdc.gov/cmv/trends-stats.htmll.
11. Kim R. Epidemiology of hepatitis B in the United States. Hepatology 2009, 49(5 suppl):S28-S34.
12. Available at:. Accessed October 30, 2014. http://www.cdc.gov/hepatitis/Statistics/2012Surveillance/Commentary.htm#hepC.
13. HIV among pregnant women, infants and children. Available at:. Accessed October 30, 2014. http://www.cdc.gov/hiv/risk/gender/pregnantwomen/facts/.
14. Prevalence of HIV, female (% ages 15-24). Available at:. Accessed October 31, 2014. http://data.worldbank.org/indicator/SH.HIV.1524.FE.ZS.
15. Maldonado A., Nizet V., Klein J., et al. Current concepts of infections of the fetus and newborn infant. Infectious diseases of the fetus and newborn infant 2011, 2-23. Elsevier Saunders, Philadelphia. 7th edition. J. Remington, J. Klein, C. Wilson (Eds.).
16. Ophthalmologic manifestations of toxoplasmosis. Available at:. Accessed October 31, 2014. http://emedicine.medscape.com/article/2044905-overview.
17. Rubella (German measles, three-day measles). Available at:. Accessed October 31, 2014. http://www.cdc.gov/rubella/about/photos.htm.
18. Redbook American Academy of Pediatrics Toxoplasmosis. Red book: 2012 report of the Committee on Infectious Disease 2012, 720-728. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
19. Toxoplasmosis. Available at:. Accessed October 30, 2014. http://www.cdc.gov/dpdx/toxoplasmosis/index.html.
20. Remington J., McLeod R., Wilson C., et al. Toxoplasmosis. Infectious diseases of the fetus and newborn infant 2011, 918-1041. Elsevier Saunders, Philadelphia. 7th edition. J. Remington, J. Klein, C. Wilson, C. Baker (Eds.).
21. Oz H. Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon. Front Microbiol 2014, 24(5):385.
22. Kieffer F., Wallon M. Congenital toxoplasmosis. Handb Clin Neurol 2013, 112:1099-1101.
23. Lindsay D.S., Dubey J.P. Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis. Parasitology 2011, 138(14):1829-1831.
24. Dubey J.P., Jones J.L. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 2008, 38(11):1257-1278.
25. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiébaut R., Leproust S., et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007, 369(9556):115-122.
26. Torgersona P., Mastroiacovob P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ 2013, 91:501-508.
27. Jones J., Kruszon-Moran D., Wilson M. Toxoplasma gondii prevalence, United States. Emerg Infect Dis 2007, 13(4):656-657.
28. Wallon M., Peyron F., Cornu C., et al. Congenital Toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 2013, 56(9):1223-1231.
29. Kieffer F., Wallon M., Garcia P., et al. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J 2008, 27(1):27-32.
30. Cortina-Borja M., Tan H., Wallon M., et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 2010, 7(10). pii:e1000351.
31. Murat J.B., Fricker H., Brenier-Pinchart M.P., et al. Human toxoplasmosis: which biological diagnostic tests are best suited to which clinical situations?. Expert Rev Anti Infect Ther 2013, 11(9):943-956.
32. de Jong E., Vossen A., Walther F., et al. How to use neonatal TORCH testing. Arch Dis Child Educ Pract Ed 2013, 98:93-98.
33. Blencow H., Cousens S., Kamb M., et al. Lives saved tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality. BMC Public Health 2011, 11(Suppl 3):S9.
34. Berman S. Maternal syphilis: pathophysiology and treatment. Bull World Health Organ 2004, 82(6):433-438.
35. Newman L., Kamb M., Hawkes S., et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational surveillance data. PLoS Med 2013, 10(2):e1001396.
36. Qui J., Yang T., Xiao S., et al. Reported estimates of adverse pregnancy outcomes among women with and without syphilis: a systematic review and meta-analysis. PLoS One 2014, 9(7):e102203.
37. Sexually transmitted disease surveillance 2012. Table28. Available at:. Accessed October 29, 2014. http://www.cdc.gov/std/stats12/Surv2012.pdf.
38. Sexually transmitted disease surveillance 2012. Table41. Available at:. Accessed October 29, 2014. http://www.cdc.gov/std/stats12/Surv2012.pdf.
39. Sexually transmitted disease surveillance 2012. Tables 42b and 43. Available at:. Accessed October 29, 2014. http://www.cdc.gov/std/stats12/Surv2012.pdf.
40. The global elimination of congenital syphilis: rationale and strategy for action. Available at:. Accessed October 29, 2014. http://www.who.int/reproductivehealth/publications/rtis/9789241595858/en/.
41. Global guidance on criteria and process for validation: elimination of mother-to-child transmission of HIV and syphilis. Available at:. Accessed October 29, 2014. http://www.aidsdatahub.org/sites/default/files/highlight-reference/document/Global_guidance:on_criteria_and_processes_for_validation_2014.pdf.
42. Gomez G., Kamb M., Newman L., et al. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. Bull World Health Organ 2013, 91(3):217-226.
43. Follett T., Clarke D. Resurgence of congenital syphilis: diagnosis and treatment. Neonatal Netw 2011, 30(5):320-328.
44. 2010 STD treatment guidelines. Available at:. Accessed October 29, 2014. http://www.cdc.gov/std/treatment/2010/toc.htm.
45. American Academy of Pediatrics Syphilis. Red book: 2012 report of the Committee on Infectious Diseases 2012, 695. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
46. Banatvala J.E., Brown D.W. Rubella. Lancet 2004, 363(9415):1127-1137.
47. Rubella. Available at:. Accessed October 29, 2014. http://www.who.int/mediacentre/factsheets/fs367/en/#.
48. Vaccine and immunizations: congenital rubella syndrome. Available at:. Accessed October 28, 2014. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt15-crs.html.
49. Given K., Lee D., Jones T., et al. Congenital rubella syndrome: ophthalmic manifestations and associated systemic disorders. Br J Ophthalmol 1993, 77:358-363.
50. Morbidity and mortality weekly report (MMWR). Available at:. Accessed October 28, 2014. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm.
51. American Academy of Pediatrics Rubella. Red book: 2012 report of the Committee on Infectious Diseases 2012, 629. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
52. American Academy of Pediatrics Parvovirus. Red book: 2012 report of the Committee on Infectious Disease 2012, 539-541. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
53. Adler S., Kock W. Human parvovirus infections. Infectious diseases of the fetus and newborn infant 2011, 834-860. Elsevier Saunders, Philadelphia. 7th edition. J. Remington, J. Klein, C. Wilson (Eds.).
54. Young N., Brown K. Mechanisms of disease: parvovirus B19. NEngl J Med 2004, 350:586-597.
55. de Jong E., Walther F., Kroes A., et al. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn 2011, 31(5):419-425.
56. Human parvovirus. Available at:. Accessed October 31, 2014. http://www.cdc.gov/parvovirusb19/pregnancy.html.
57. Bonvicini F., Puccetti C., Salfi N., et al. Gestational and fetal outcomes in B19 maternal infection: a problem of diagnosis. JClin Microbiol 2011, 49:3514-3518.
58. Dijkmans A., de Jong E., Dijkmans B., et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr Opin Obstet Gynecol 2012, 24(2):95-101.
59. Lamont R., Sobel J., Vaisbuch E., et al. Parvovirus B19 infection in human pregnancy. BJOG 2011, 118(2):175-186.
60. Isumi H., Nunoue T., Nishida A., et al. Fetal brain infection with human parvovirus B19. Pediatr Neurol 1999, 21:661-663.
61. Heegaard E., Hasle H., Skibsted L., et al. Congenital anemia caused by parvovirus B19 infection. Pediatr Infect Dis J 2000, 19(12):1216-1218.
62. Hudson A., Montegudo A., Steele R. Congenital human parvovirus B19 infection with persistent viremia. Clin Pediatr 2014, 1-5. 10.1177/0009922814533412.
63. De Jong E., Lindenburg I., van Klink J., et al. Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome. Am J Obstet Gynecol 2012, 206(3):204.e1-204.e5.
64. Lassen J., Bager P., Wohlfahrt J., et al. Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring. Int J Epidemiol 2013, 42(4):1070-1076.
65. Lindenburg I., van Klink J., Smits-Wintjens V., et al. Long-term neurodevelopmental and cardiovascular outcome after intrauterine transfusions for fetal anaemia: a review. Prenat Diagn 2013, 33(9):815-822.
66. Nesheim S., Taylor A., Lampe M.A., et al. Aframework for elimination of perinatal transmission of HIV in the United States. Pediatrics 2012, 130(4):738-744.
67. Centers for Disease Control and Prevention. HIV surveillance report 2011, vol. 23. 2013. Available at:. Accessed October 7, 2014. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/.
68. World Health Organization. Global update on the health sector response to HIV, 2014. 2014. Available at:. Accessed October 31, 2014. http://apps.who.int/iris/bitstream/10665/128494/1/9789241507585_eng.pdf?ua=1.
69. John G., Nduati R., Mbori-Ngacha D., et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 shedding and breast infections. JInfect Dis 2001, 183:206-212.
70. Fowler M.G., Kourtis A.P., Aizire J., et al. Breastfeeding and transmission of HIV-1: epidemiology and global magnitude. Adv Exp Med Biol 2012, 743:3-25.
71. Drake A.L., Wagner A., Richardson B., et al. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med 2014, 11(2):e1001608.
72. Kourtis A.P., Bulterys M., Nesheim S.R., et al. Understanding the timing of HIV transmission from mother to infant. JAMA 2001, 285:709.
73. Landesman S.H., Kalish L.A., Burns D.N., et al. Obstetrical factors and the transmission of HIV. Curr HIV Res 2013, 11:10.
74. American Academy of Pediatrics Committee on Pediatric AIDS HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics 2008, 122(5):1127-1134.
75. Mofenson L.M. Technical report: perinatal human immunodeficiency virus testing and prevention of transmission. Committee on Pediatric Aids. Pediatrics 2000, 106(6):E88.
76. US Preventive Services Task Force Screening for HIV: recommendation statement. Ann Intern Med 2005, 143(1):32-37.
77. Branson B.M., Handsfield H.H., Lampe M.A., et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006, 55(RR-14):1-17. [quiz: CE1-4].
78. American College of Obstetrics and Gynecology Committee on Obstetric Practice ACOG Committee Opinion No. 418: prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2008, 112(3):739-742.
79. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at:. Accessed October 19, 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf.
80. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at:. Accessed October 31, 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf.
81. Violari A., Cotton M.F., Gibb D.M., et al. Early antiretroviral therapy and mortality among HIV-infected infants. NEngl J Med 2008, 359(21):2233-2244.
82. Laughton B., Cornell M., Grove D., et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012, 26(13):1685-1690.
83. Persaud D., Gay H., Ziemniak C., et al. Absence of detectable viremia after treatment cessation in an infant. NEngl J Med 2013, 369:1828-1835.
84. NIH news press release Thursday July 10, 2014. "Mississippi Baby" now has detectable virus, researchers find. Available at:. Accessed October 31, 2014. http://www.niaid.nih.gov/news/newsreleases/2014/Pages/MississippiBabyHIV.aspx.
85. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at:. Accessed October 29, 2014. [page 27, Tableonly section]. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
86. Chang M. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007, 12(3):160-167.
87. Karnsahul W., Schwarz K. Hepatitis B. Infectious diseases of the fetus and newborn infant 2011, 803-806. Elsevier Saunders, Philadelphia. 7th edition. J. Remington, J. Klein, C. Wilson (Eds.).
88. American Academy of Pediatrics Hepatitis B. Red book: 2012 report of the Committee on Infectious Disease 2012, 369-390. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
89. Tran T. Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol 2011, 7(8):511-516.
90. Bleich L., Swenson E. Prevention of neonatal hepatitis B virus transmission. JClin Gastroenterol 2014, 48(9):765-772.
91. Tran T. Hepatitis B: treatment to prevent perinatal transmission. Clin Obstet Gynecol 2012, 55(2):541-549.
92. Milich D., Liang T. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003, 38:1075-1086.
93. Hwang E., Cheung R. Global epidemiology of hepatitis B virus (HBV) infection. NAm J Med Sci 2011, 4(1):7-13.
94. Available at:. Accessed October 30, 2014. http://https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_b/perinatal/docs/program_manual.pdf.
95. US Preventive Services Task Force Screening for hepatitis B virus infection in pregnancy: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009, 150(12):869-873.
96. Kubo A., Shlager L., Marks A.R., et al. Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med 2014, 160(12):828-835.
97. Lee C., Gong Y., Brok J., et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006, (2). CD004790. 10.1002/14651858.CD004790.pub2.
98. CDC Acomprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54:RR-16.
99. Available at:. Accessed October 31, 2014. http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html.
100. Karnsahul W., Schwarz K. Hepatitis C. Infectious diseases of the fetus and newborn infant 2011, 806-808. Elsevier Saunders, Philadelphia. 7th edition. J. Remington, J. Klein, C. Wilson (Eds.).
101. American Academy of Pediatrics Hepatitis C. Red book: 2012 report of the Committee on Infectious Diseases 2012, 391-395. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
102. Jahveri R., Swamy G. Hepatitis C virus in pregnancy and early childhood: current understanding and knowledge deficits. J Pediatric Infect Dis Soc 2014, 3(Suppl1):S13-S18.
103. Wen J., Haber B. Maternal-fetal transmission of hepatitis C infection: what is so special about babies?. JPediatr Gastroenterol Nutr 2014, 58(3):278-282.
104. Mast E., Hwang L., Seto D., et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. JInfect Dis 2005, 192:1880.
105. Indolfi G., Azzari C., Resti M Perinatal transmission of hepatitis C virus. JPediatr 2013, 163(6):1549-1552.
106. Bevilacqua E., Fabris A., Floreano P., et al. Genetic factors in mother-to-child transmission of HCV infection. Virology 2009, 390:64-70. EPHN Collaborators.
107. Benova L., Mohamoud Y., Calvert C., et al. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014, 59(6):765-773.
108. Indolfi G., Resti M. Perinatal transmission of hepatitis C virus infection. JMed Virol 2009, 81(5):836-843.
109. Available at:. Accessed October 29, 2014. http://www.cdc.gov/hepatitis/HCV/Management.htm#section1.
110. Cottrell E., Chou R., Wasson N., et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2013, 158(2):109-113.
111. Mack C.L., Gonzalez-Peralta R.P., Gupta N., et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. JPediatr Gastroenterol Nutr 2012, 54:838-855.
112. Available at:. Accessed October 30, 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/.
113. Parasites-toxoplasmosis (Toxoplasma infection). Available at:. Accessed October 31, 2014. http://www.cdc.gov/parasites/toxoplasmosis/gen_info/pregnant.html.